Harmony Biosciences (HRMY)

Executive Summary

Harmony Biosciences is a commercial-stage biopharmaceutical company focused on rare neurological diseases, with a lead product, pitolisant (Wakix), approved for narcolepsy. The company has established a strong commercial foundation, generating significant revenue from Wakix, and is expanding its pipeline into idiopathic hypersomnia (IH), Prader-Willi syndrome (PWS), and rare epilepsies (Dravet and Lennox-Gastaut syndromes) via clemizole. Recent Phase 3 data for pitolisant in IH were positive, and the company plans to file a supplemental NDA in 2026. Phase 3 trials for clemizole in Dravet and LGS are recruiting, with data expected in 2027-2029. The PWS program for pitolisant is also in Phase 3. With a validated commercial platform and multiple late-stage catalysts, Harmony is positioned for sustained growth, though pipeline execution and market adoption remain key risks.

Upcoming Catalysts (preview)

• H2 2026Pitolisant sNDA submission for Idiopathic Hypersomnia80% success
• 2027Phase 3 CLEM trial data for Dravet syndrome (clemizole)55% success
• 2028Phase 3 pitolisant data for Prader-Willi syndrome60% success